查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2034526

2026-2034年全球升糖素市場規模、佔有率、趨勢和成長分析報告

Global Glucagon Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 152 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球升糖素市場預計將從2025年的3.5883億美元成長至2034年的6.7031億美元，2026年至2034年的複合年成長率（CAGR）為7.19%。該市場正經歷穩定成長，主要得益於糖尿病盛行率的上升以及對嚴重低血糖緊急治療需求的增加。升糖素是一種用於升高血糖值的激素，常用於低血糖緊急情況。全球糖尿病患者人數的不斷增加是市場成長的主要驅動力，這主要源於對有效快速治療方法的需求不斷成長。此外，人們對糖尿病管理和緊急準備意識的提高也促進了升糖素產品的應用。

推動成長的因素包括製劑和給藥系統的進步，這些進步提高了易用性和有效性。即用型胰高升糖素盒和鼻內製劑的開發提高了患者的便利性和可及性。越來越多的醫療專業人員將升糖素的普及。

預計升糖素市場將持續創新發展。各公司將致力於研發更易於使用且更穩定的配方。數位健康技術和連網型設備的整合將進一步改善患者監測和治療效果。隨著公眾意識的提高和醫療服務可近性的不斷改善，預計該市場將穩步成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業的市場定位、產品系列、策略舉措和財務表現進行了詳細評估。這為了解競爭趨勢和主要參與者所採取的策略提供了寶貴的見解。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球升糖素市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 注射藥物
  • 吸入

第5章：全球升糖素市場：依應用分類

  • 市場分析、洞察與預測
  • 低血糖
  • 診斷輔助

第6章 全球升糖素市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 藥局和零售藥房
  • 網路藥房

第7章 全球升糖素市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Novo Nordisk A/S
    • Fresenius SE & Co. KGaA
    • Amphastar Pharmaceuticals Inc
    • Xeris Biopharma Holdings Inc
    • ILS Inc
    • United Biotech（P）Limited
    • Zealand Pharma A/S
    • Taj Pharmaceuticals Limited
    • Eli Lilly And Company
    • Bayer AG
    • Torrent Pharmaceuticals Ltd
簡介目錄
Product Code: VMR11216245

The global glucagon market size is expected to reach USD 670.31 Million in 2034 from USD 358.83 Million in 2025, growing at a CAGR of 7.19 during 2026-2034.This market is experiencing steady growth due to the increasing prevalence of diabetes and the rising need for emergency treatments for severe hypoglycemia. Glucagon is a hormone used to raise blood glucose levels and is commonly administered during hypoglycemic emergencies. The growing global diabetic population is a major factor driving market growth, as the need for effective and rapid treatment options continues to rise. Additionally, increasing awareness about diabetes management and emergency preparedness is supporting the adoption of glucagon products.

Growth drivers include advancements in pharmaceutical formulations and delivery systems that improve ease of use and effectiveness. The development of ready-to-use glucagon kits and nasal formulations has enhanced patient convenience and accessibility. Healthcare providers are increasingly recommending glucagon as part of diabetes management plans, further supporting market growth. Furthermore, the expansion of healthcare infrastructure and improved access to medical services in emerging regions are contributing to increased adoption.

Looking ahead, the glucagon market is expected to witness continuous innovation and development. Companies are likely to focus on developing more user-friendly and stable formulations. The integration of digital health technologies and connected devices will further improve patient monitoring and treatment outcomes. As awareness and healthcare access continue to improve, the market is anticipated to grow steadily.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Route of Administration

  • Injectable
  • Inhalation

By Application

  • Hypoglycemia
  • Diagnostic Aid

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Novo Nordisk A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals Inc., Xeris Biopharma Holdings Inc., ILS Inc., United Biotech (P) Limited, Zealand Pharma A/S, Taj Pharmaceuticals Limited., Eli Lilly and Company, Bayer AG, Torrent Pharmaceuticals Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL GLUCAGON MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Route Of Administration
  • 4.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Inhalation Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GLUCAGON MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Hypoglycemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Diagnostic Aid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GLUCAGON MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Drug Stores & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GLUCAGON MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Route Of Administration
    • 7.2.2 By Application
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Route Of Administration
    • 7.3.2 By Application
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Route Of Administration
    • 7.4.2 By Application
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Route Of Administration
    • 7.5.2 By Application
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Route Of Administration
    • 7.6.2 By Application
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GLUCAGON INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Novo Nordisk A/S
    • 9.2.2 Fresenius SE & Co. KGaA
    • 9.2.3 Amphastar Pharmaceuticals Inc
    • 9.2.4 Xeris Biopharma Holdings Inc
    • 9.2.5 ILS Inc
    • 9.2.6 United Biotech (P) Limited
    • 9.2.7 Zealand Pharma A/S
    • 9.2.8 Taj Pharmaceuticals Limited
    • 9.2.9 Eli Lilly And Company
    • 9.2.10 Bayer AG
    • 9.2.11 Torrent Pharmaceuticals Ltd